Stable Supply of Reliable, Safe and Affordable Generic Active Pharmaceutical Ingredients
First written in FY2018. 17 of 27 entries say "Restated". Latest entry: FY2026.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, we are proceeding with construction of the Zao No. 2 Plant to fulfill our responsibility to ensure a stable supply and respond to further growth in demand, and the plant was completed in June 2026.」
The policy for stable supply cites the specific progress that the Zao No. 2 Plant was completed in June 2026. - FY2026-H1Added response to supply shortages through increased productionAnnual report
「Our group also works to ensure stable supply by increasing production when products with the same efficacy and ingredients supplied by other companies face shortages.」
The group newly stated that it increases production when competing products face supply shortages. - FY2025RestatedAnnual report
「In the pharmaceutical manufacturing and marketing business, construction of the Zao No. 2 Plant is proceeding as planned for operations to begin in July 2027, in order to fulfill our responsibility to ensure stable supply and accommodate further demand growth.」
The group continues to state its policy of accommodating demand growth and ensuring a stable supply of pharmaceuticals, including through construction of the Zao No. 2 Plant. - FY2025-H1AdvancedAnnual report
「During the interim consolidated accounting period, the API sales business continued to expand the use of the Osaka Pharmaceutical Analysis Center, which underwent renovation in the previous fiscal year, to accommodate further growth in transaction volumes. In the pharmaceutical manufacturing and marketing business, construction of the Zao No. 2 Plant is proceeding as planned for operations to begin in July 2027, in order to fulfill our responsibility to ensure stable supply and accommodate further demand growth.」
The group stated that it is proceeding as planned with the use of the Osaka Pharmaceutical Analysis Center and construction of the Zao No. 2 Plant for operations to begin in July 2027. - FY2024Publication of stable supply informationAnnual report
「With respect to information disclosure, コーアイセイ株式会社 and コーアバイオテックベイ株式会社, which are part of the pharmaceutical manufacturing and marketing business, publish information related to stable supply on their respective websites.」
The group explicitly stated that, in addition to strengthening quality and manufacturing controls, information related to stable supply is published on the websites of its pharmaceutical manufacturing and marketing subsidiaries. - FY2024-Q3AdvancedAnnual report
「In the pharmaceutical manufacturing and marketing business, as we pursue our medium- to long-term growth strategy of becoming a leading manufacturer of distinctive injectables, the pharmaceutical warehouse being built at the Zao Plant began operations in March 2024.」
As a concrete development under the stable supply policy, the pharmaceutical warehouse at the Zao Plant began operations in March 2024. - FY2024-Q2RestatedAnnual report
「In our API sales business, we maintain a stable supply of high-quality, cost-competitive pharmaceutical APIs.」
The policy of stably supplying high-quality, cost-competitive APIs has been reaffirmed. - FY2024-Q1RestatedAnnual report
「Although supply concerns continue across the generic-drug industry, our group continues to strengthen manufacturing controls and quality controls」
Amid continuing supply concerns across the generic-drug industry, the group has reaffirmed its policy of strengthening manufacturing and quality controls and maintaining stable supply. - FY2023Formalization of a social objectiveAnnual report
「Against this business backdrop, our group will focus on the following issues in order to realize a society that contributes to the stable supply of generic drugs and leaves no one without the medicines they need.」
In addition to its existing stable supply policy, the group has formalized the type of society it seeks to realize through stable supply. - FY2023-Q3AdvancedAnnual report
「Among the injectables that are a strength of our pharmaceutical manufacturing and marketing business, the gap from prevailing market prices is small. We are focusing in particular on manufacturing highly potent injectables, for which substitution by generic drugs has been relatively limited, while working to further improve productivity. As part of these efforts, we decided to build a new pharmaceutical warehouse on the site of the Zao Plant in order to increase production of products for which further demand growth is expected and establish a stable supply system. The warehouse will strengthen production capacity by securing stable inventories of raw materials and increasing the number of products manufactured. By improving our stable supply system, we aim to further expand the pharmaceutical manufacturing and marketing business.」
As part of the stable supply policy, the group decided to build a new pharmaceutical warehouse on the site of the Zao Plant. The initiative is intended to improve the stable supply system by securing stable inventories of raw materials, increasing production and strengthening production capacity. - FY2023-Q2RestatedAnnual report
「Building on the strengths of our pharmaceutical manufacturing and marketing business, our group is focusing on manufacturing highly potent injectables, where substitution by generic drugs has been relatively limited, while working to further improve productivity and ensure a stable supply of pharmaceuticals required by healthcare professionals.」
The group continues to state its policy of focusing on highly potent injectables and ensuring a stable supply of pharmaceuticals required by healthcare professionals. - FY2023-Q1RestatedAnnual report
「We will work to ensure a stable supply of pharmaceuticals required by healthcare professionals.」
The policy of ensuring a stable supply of pharmaceuticals continues to be stated. - FY2022-Q3RestatedAnnual report
「We will work to ensure a stable supply of pharmaceuticals required by healthcare professionals.」
The stable supply of pharmaceuticals required by healthcare professionals continues to be upheld. - FY2022-Q2RestatedAnnual report
「Against this backdrop, based on our management policy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables. We stably supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical companies.」
The stable supply of high-quality, low-cost APIs to the Japanese market and the business model, including contract manufacturing, continue to be upheld. - FY2022-Q1RestatedAnnual report
「Against this backdrop, based on our business philosophy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables. We stably supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical companies.」
The policy of stably supplying high-quality, low-cost APIs to the Japanese market and the business model, including contract manufacturing, have been reaffirmed. - FY2021RestatedAnnual report
「In the API sales business, コーア商事株式会社 will continue supplying APIs for safe, reliable and affordable generic drugs」
The policy of stable supply of safe, reliable and affordable generic-drug APIs has been reaffirmed. - FY2021-Q2RestatedAnnual report
「Against this backdrop, based on our business philosophy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables, and stably supplies high-quality, low-cost APIs to the Japanese market」
The policy of stably supplying high-quality, low-cost APIs to the Japanese market has been reaffirmed together with an explanation of the business philosophy and business model. - FY2021-Q1RestatedAnnual report
「Against this backdrop, based on our business philosophy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables. We stably supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical companies.」
The policy of stably supplying high-quality, low-cost APIs to the Japanese market has been reaffirmed together with an explanation of the business model. - FY2020-Q3RestatedAnnual report
「As a company involved in the pharmaceutical industry, which protects public health, our group will continue working to ensure a stable supply of pharmaceuticals.」
The group explicitly stated its policy of continuing to ensure a stable supply of pharmaceuticals even during the spread of COVID-19. - FY2020-Q2RestatedAnnual report
「Against this backdrop, our group imports and sells APIs, the raw materials for pharmaceuticals, with a focus on providing high-quality, low-cost imported APIs. We also develop, manufacture and sell finished pharmaceutical products, primarily injectables, and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure that enables integrated manufacturing from API procurement through finished products.」
The provision of high-quality, low-cost imported APIs and an integrated structure covering API procurement through finished products continue to serve as the business foundation. - FY2020-Q1RestatedAnnual report
「Against this backdrop, our group imports and sells APIs, the raw materials for pharmaceuticals, with a focus on providing high-quality, low-cost imported APIs. We also develop, manufacture and sell finished pharmaceutical products, primarily injectables, and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure that enables integrated manufacturing from API procurement through finished products.」
The provision of high-quality, low-cost imported APIs and an integrated structure covering API procurement through finished products continue to serve as the business foundation. - FY2019RestatedAnnual report
「To achieve this, in the API sales business, コーア商事株式会社 will continue supplying APIs for safe, reliable and affordable generic drugs」
The policy of continuing to supply safe, reliable and affordable APIs for generic drugs has been reaffirmed. - FY2019-Q3RestatedAnnual report
「Against this backdrop, our group imports and sells APIs, the raw materials for pharmaceuticals, with a focus on providing high-quality, low-cost imported APIs. We also develop, manufacture and sell finished pharmaceutical products, primarily injectables, and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure that enables integrated manufacturing from API procurement through finished products.」
The business policy of emphasizing the provision of high-quality, low-cost imported APIs has been reaffirmed. - FY2018First statedAnnual report
「We will continue supplying APIs for safe, reliable and affordable generic drugs」
An ongoing supply policy for the API sales business.